How should I manage a patient who finds Vyvanse (lisdexamfetamine) ineffective and costly, is taking Adderall immediate‑release (IR) that works, wants to switch to Adderall XR, and the pharmacy is concerned about overlapping stimulant use?

Managing Overlapping Stimulant Prescriptions and Medication Switching in ADHD

You need to immediately clarify the medication regimen with the patient and pharmacy, discontinue the Vyvanse since she reports it doesn't work, and transition her fully to Adderall XR with proper documentation to prevent concerns about diversion or misuse.

Immediate Steps to Address Pharmacy Concerns

The pharmacy's concern about overlapping stimulant prescriptions is legitimate and requires urgent clarification 1. This situation raises red flags for potential:

• Medication diversion or misuse – a critical concern with controlled substances 2
• Inappropriate polypharmacy – taking multiple stimulants simultaneously is not standard practice 1
• Safety risks – overlapping stimulants increase cardiovascular and psychiatric adverse event risks 2

Contact the patient immediately to determine:

• Whether she picked up the Vyvanse prescription despite reporting it ineffective
• If she is taking both medications concurrently
• Her understanding of the treatment plan 1

Proper Medication Transition Protocol

Discontinue Vyvanse Completely

Since the patient reports Vyvanse is ineffective and expensive, there is no clinical justification to continue it 1. Document clearly in the medical record that Vyvanse was discontinued due to lack of efficacy 1.

• Instruct the patient to stop taking Vyvanse immediately if she has been using it 1
• Advise proper disposal of unused Vyvanse to prevent diversion 2
• Contact the pharmacy to cancel any remaining Vyvanse refills 1

Transition to Adderall XR

Since Adderall IR was effective, transitioning to Adderall XR is clinically appropriate 1. The extended-release formulation provides:

• Once-daily dosing – improving adherence and reducing stigma from school administration 1
• Smoother symptom control – reducing rebound effects common with immediate-release formulations 1
• Lower diversion risk – compared to immediate-release formulations 1

Conversion approach 1:

• Calculate the total daily dose of Adderall IR that was effective
• Prescribe an equivalent total daily dose of Adderall XR once daily in the morning
• For example: If she responded to 10 mg Adderall IR twice daily (20 mg total), prescribe Adderall XR 20 mg once daily 1

Titration and Monitoring

Initial monitoring schedule 1:

• Weekly contact (phone or in-person) during the first 2-4 weeks of Adderall XR
• Assess target ADHD symptoms using standardized rating scales from multiple sources 1
• Monitor for side effects: appetite suppression, insomnia, cardiovascular changes, mood symptoms 1
• Check blood pressure, pulse, weight at each visit 1

Dose adjustments 1:

• If symptoms inadequately controlled, increase by 5-10 mg weekly increments
• Maximum dose typically 50-70 mg daily, though individual response varies 1
• Some patients may benefit from a small afternoon IR dose for homework/evening coverage 1

Documentation and Communication

Medical Record Documentation

Document thoroughly 1:

• Vyvanse trial was adequate in dose and duration but ineffective
• Patient reported cost concerns with Vyvanse
• Adderall IR trial showed clinical benefit
• Rationale for switching to Adderall XR (efficacy, adherence, convenience)
• Patient education provided about proper use and storage 2

Pharmacy Communication

Contact the pharmacy directly 1:

• Explain the medication switch and discontinuation of Vyvanse
• Clarify that overlapping prescriptions were unintentional
• Ensure only Adderall XR prescriptions are active going forward
• Consider using your state's prescription drug monitoring program (PDMP) to track controlled substance prescriptions 1

Addressing Abuse and Diversion Risk

Patient Education

Educate the patient about 2:

• Proper storage in a secure, preferably locked location
• Never sharing medication with others
• Risks of misuse, abuse, and addiction with stimulants
• Proper disposal of unused medication
• Signs of misuse to monitor for 1

Ongoing Monitoring

Throughout treatment, monitor for 2:

• Signs of misuse: requesting early refills, "lost" prescriptions, dose escalation without clinical justification
• Diversion: discrepancies in pill counts, reports from pharmacy
• Use your state's PDMP regularly to check for multiple prescribers 1

Special Considerations for Adolescents

If this is an adolescent patient 1:

• Screen for substance use before and during treatment
• Consider longer-acting formulations to minimize diversion risk at school
• Monitor prescription refill patterns more closely
• Involve parents/guardians in medication management and monitoring

Common Pitfalls to Avoid

• Never maintain overlapping stimulant prescriptions without clear clinical justification and documentation 1
• Don't ignore pharmacy concerns – they serve as an important safety check 1
• Avoid inadequate documentation of medication changes, which can raise concerns about prescribing practices 1
• Don't skip cardiovascular screening before initiating or changing stimulants, especially checking for cardiac disease risk factors 2
• Never assume the patient understands the treatment plan – explicit verbal and written instructions are essential 1